Hologic has signed a definitive agreement for the acquisition of Gynesonics, which develops minimally invasive solutions for women’s health, in a deal valued at approximately $350m.

This strategic move is set to enhance Hologic's portfolio in women's health by integrating Gynesonics’ Sonata System, a technology intended for the treatment of symptomatic uterine fibroids.

The Sonata System is the first Food and Drug Administration (FDA)-cleared medical device that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation. This incisionless procedure is designed for diagnostic imaging and trans-cervical uterine fibroids treatment, including those that cause heavy menstrual bleeding.

Hologic Surgical Solutions division president Brandon Schnittker said: “Gynesonics’ Sonata System complements our offering and will give GYN surgeons across the globe an expanded range of options to treat women suffering from heavy periods and fibroids.

“This acquisition furthers our commitment to providing women with minimally invasive treatment options. We are enthusiastic about the future as we work to expand access to and drive innovation for treatments that enhance women’s quality of life.”

The completion of the acquisition is pending customary closing conditions, which include the receipt of necessary regulatory clearances.

The Sonata System has already made a significant impact, with more than 10,000 women treated globally as of August 2024.

Gynesonics launched a new SMART OS 2.4 software technology for the Sonata System in September 2024, indicating ongoing innovation in this medical technology.

In July 2024, Hologic expanded its surgical portfolio by acquiring Endomagnetics, a UK-based developer of breast cancer surgery technologies, for approximately $310m.

Endomag develops technologies for breast surgery, including the Magseed marker, Magtrace lymphatic tracing injectable and Sentimag platform.